Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 10/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179061 | 0.84 | PDE4B (0.47) | DRD2MEN1KMT2AHTR2C | |
| SCHEMBL22063773 | 0.82 | PDE4B (0.48) | DRD2MEN1KMT2AMAPT | |
| SCHEMBL824153 | 0.81 | DRD2 (0.69) | DRD2MEN1KMT2AHTR2CMAPT | |
| SCHEMBL1515163 | 0.80 | HTR2C (0.75) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL13917718 | 0.78 | MEN1 (0.72) | DRD2MEN1KMT2AHTR2CMAPT | |
| SCHEMBL2637185 | 0.78 | MEN1 (0.77) | DRD2MEN1KMT2AHTR2CMAPT | |
| SCHEMBL13450162 | 0.78 | HTR2C (0.53) | HTR2C | |
| SCHEMBL20400164 | 0.78 | MEN1 (0.54) | DRD2MEN1KMT2AHTR2CMAPT | |
| SCHEMBL20400103 | 0.78 | MEN1 (0.53) | DRD2MEN1KMT2AHTR2CMAPT | |
| SCHEMBL12099491 | 0.77 | PDE4B (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | DRD2 187/4885MEN1 596/4885KMT2A 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.